Risk of acute adrenal insufficiency when switching from crushed or compounded oral hydrocortisone formulations to Alkindi (hydrocortisone granules in capsules for opening)
About
This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.
Documents
Key facts
| Medicine name |
Alkindi
|
| Active substance |
hydrocortisone
|
| Therapeutic area (MeSH) |
Adrenal Insufficiency
|
| Regulatory outcome |
Variation
|
| DHPC type |
Safety signal
|
| Human ATC code |
H02AB09
|
| Dissemination date |
04/02/2021
|